穴位贴敷鼻敏通能量贴治疗过敏性鼻炎的疗效观察

【目的】观察穴位贴敷鼻敏通能量贴治疗过敏性鼻炎的临床疗效。【方法】将100例过敏性鼻炎患者随机分为观察组和对照组,每组各50例。观察组给予穴位贴敷鼻敏通能量贴治疗,选取迎香穴、神阙穴,每天1次,每次持续贴敷8 h,每周治疗5次,共治疗4周;对照组给予氯雷他定片口服治疗,每天1次,每次1片,每周治疗5次,连续服用4周。观察2组患者治疗前后及治疗后3个月随访时鼻症状视觉模拟量表(VAS)评分、鼻伴随症状VAS评分、鼻症状总积分表(TNSS)、鼻伴随症状总分表(TNNSS)、鼻结膜炎生存质量量表(RQLQ)评分和血清总免疫球蛋白E(IgE)、嗜酸性粒细胞(EOS)总数变化,并评价2组的不良反应及安全性。【结果】(1)治疗1、2、3、4周后及治疗3个月后随访时,2组患者的鼻症状VAS评分、鼻伴随症状VAS评分均明显改善,与治疗前比较,差异具有统计学意义(P<0.05);治疗完成3月后随访,观察组鼻症状VAS评分、鼻伴随症状VAS评分均改善明显,与对照组比较,差异有统计学意义(P<0.05);但治疗1、2、3、4周后,2组间鼻症状VAS评分比较,差异无统计学意义(P>0.05)。(2)治疗2、4周后,2组患者的TNSS评分明显改善,与同组治疗前比较,差异有统计学意义(P<0.05);治疗2、4周后,2组间TNSS评分比较,差异无统计学意义(P>0.05)。(3)治疗2、4周后,观察组患者的TNNSS评分均明显改善,与同组治疗前比较,差异有统计学意义(P<0.05);对照组TNNSS评分稍有改善,但与同组治疗前比较,差异无统计学意义(P>0.05);治疗2、4周后,观察组的TNNSS评分改善明显,与同期对照组比较,差异有统计学意义(P<0.05)。(4)治疗2、4周后,2组患者的RQLQ评分均明显改善,与同组治疗前比较,差异有统计学意义(P<0.05);治疗2、4周后,2组RQLQ评分稍有改善,但与同期对照组比较,差异无统计学意义(P>0.05)。(5)治疗4周后,2组患者的总IgE及EOS水平稍有改善,但与同组治疗前比较,差异无统计学意义(P>0.05)。观察组患者的总IgE及EOS水平稍有改善,但与同期对照组比较,差异无统计学意义(P>0.05)。(6)所有患者完成了全部疗程,2组患者安全性比较,差异无统计学意义(P>0.05)。【结论】穴位贴敷鼻敏通能量贴可有效改善过敏性鼻炎患者的临床症状,提高患者生活质量,疗效显著。

Clinical Observation on Acupoint Application with Bimintong-Energy Patch for Treatment of Allergic Rhinitis

Objective To observe the clinical efficacy of acupoint application with Bimintong-Energy Patch for allergic rhinitis.Methods A total of 100 cases of patients with allergic rhinitis were randomly divided into observation group and control group,50 cases in each group.The observation group received acupoint application with Bimintong-Energy Patch at Yingxiang(LI20)and Shenque(CV8)points,once a day,8 hours per time,5 times per week,the treatment lasting 4 weeks.The control group received loratadine tablets orally once a day,one tablet per time,5 times a week,the treatment lasting 4 weeks.The changes in visual analogue scale(VAS)nasal symptom scores,VAS non-nasal symptom scores,total nasal symptom scale(TNSS)scores,total nonnasal symptoms score(TNNSS),rhino-conjunctivitis quality of life questionnaire(RQLQ)score and serum total immune globulin(IgE)and eosnophils count in the two groups were observed before and after treatment,and 3 months after treatment,and the safety in the two groups was evaluated.Results(1)After one,2,3,4 weeks of treatment and during follow-up after 3 months of treatment,the VAS nasal symptom scores and VAS non-nasal symptom scores in the two groups were improved,the differences being significant in comparison to those before treatment(P<0.05).During follow-up after 3 months of treatment,the VAS nasal symptom scores and VAS nonnasal symptom scores in the observation group were improved,the differences being significant in comparison to those in the control group(P<0.05),but after one,2,3,4 weeks of treatment,there was no significant difference in VAS nasal symptom scores between the two groups(P>0.05)(.2)After 2,4 weeks of treatment,the TNSS scores in the two groups were improved,the differences being significant in comparison to those before treatment(P<0.05).After 2,4 weeks of treatment,there was no significant difference in TNSS scores between the two groups(P>0.05).(3)After 2,4 weeks of treatment,the TNNSS scores in the observation group were improved,the differences being significant in comparison to those before treatment(P<0.05),and the TNNSS scores in the control group were improved,but the differences being insignificant in comparison to those before treatment(P>0.05).After 2,4 weeks of treatment,the TNNSS scores in the observation group were improved,the differences being significant in comparison to those in the control group during the same period(P<0.05).(4)After 2,4 weeks of treatment,the RQLQ scores in the two groups were improved,the differences being significant in comparison to those before treatment(P<0.05).After 2,4 weeks of treatment,the RQLQ scores in the observation group were improved,but the differences being insignificant in comparison to those in the control group during the same period(P>0.05).(5)After 4 weeks of treatment,the total IgE and EOS levels in the two groups were improved,but the differences being insignificant in comparison to those before treatment(P<0.05),and the total IgE and EOS levels in the observation group were improved,but the differences being insignificant in comparison to those in the control group during the same period(P>0.05).(6)All the patients completed the treatment course.There was no significant difference in safety between the two groups(P>0.05).Conclusion Acupoint application with Bimintong-Energy Patch is effective for improving the clinical symptoms of the allergic rhinitis patients,and promoting quality of life of the patients.